The FASEB Journal, Vol 6, 2349-2353, Copyright © 1992 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor

H Rupp, V Elimban and NS Dhalla
Division of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Winnipeg, Canada.

To examine the signals regulating cardiac growth and molecular structure of subcellular organelles, cardiac hypertrophy was induced in rats by constriction of the abdominal aorta for 12-13 wk or by treatment with a carnitine palmitoyltransferase I inhibitor, etomoxir (12-15 mg/kg body wt) for 12-13 wk. In contrast to pressure overload, etomoxir redistributed the myosin isozyme population from V3 to V1 and increased the sarcoplasmic reticulum (SR) Ca(2+)-stimulated ATPase activity. When rats with pressure-overloaded hearts were treated with etomoxir, the cardiac hypertrophy was increased whereas the shift in myosin isozymes from V1 to V3 was prevented and the depression in SR Ca(2+)-stimulated ATPase activity was reversed. Plasma thyroid hormone and insulin concentrations were not altered but triglyceride concentrations were reduced in etomoxir-treated rats with pressure overload. The data demonstrate a dissociation between cardiac muscle growth and changes in subcellular organelles and indicate that a shift in myocardial substrate utilization may represent an important signal for molecular remodeling of the heart.

This article has been cited by other articles:

				R. W. Schwenk, J. J.F.P. Luiken, A. Bonen, and J. F.C. Glatz Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease Cardiovasc Res, July 15, 2008; 79(2): 249 - 258. [Abstract] [Full Text] [PDF]

				P. T. Fueger, C. Y. Li, J. E. Ayala, J. Shearer, D. P. Bracy, M. J. Charron, J. N. Rottman, and D. H. Wasserman Glucose kinetics and exercise tolerance in mice lacking the GLUT4 glucose transporter J. Physiol., July 15, 2007; 582(2): 801 - 812. [Abstract] [Full Text] [PDF]

				G. Foldes, S. Vajda, Z. Lako-Futo, B. Sarman, R. Skoumal, M. Ilves, R. deChatel, I. Karadi, M. Toth, H. Ruskoaho, et al. Distinct modulation of angiotensin II-induced early left ventricular hypertrophic gene programming by dietary fat type J. Lipid Res., June 1, 2006; 47(6): 1219 - 1226. [Abstract] [Full Text] [PDF]

				N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]

				Y. Saburi, K. Okumura, H. Matsui, K. Hayashi, H. Kamiya, R. Takahashi, K. Matsubara, and M. Ito Changes in distinct species of 1,2-diacylglycerol in cardiac hypertrophy due to energy metabolic disorder Cardiovasc Res, January 1, 2003; 57(1): 92 - 100. [Abstract] [Full Text] [PDF]

				C. L. Merrill, H. Ni, L. W. Yoon, M. A. Tirmenstein, P. Narayanan, G. R. Benavides, M. J. Easton, D. R. Creech, C. X. Hu, D. C. McFarland, et al. Etomoxir-Induced Oxidative Stress in HepG2 Cells Detected by Differential Gene Expression Is Confirmed Biochemically Toxicol. Sci., July 1, 2002; 68(1): 93 - 101. [Abstract] [Full Text] [PDF]

				M. E. Young, P. McNulty, and H. Taegtmeyer Adaptation and Maladaptation of the Heart in Diabetes: Part II: Potential Mechanisms Circulation, April 16, 2002; 105(15): 1861 - 1870. [Full Text] [PDF]

				A. Zahabi and C. F. Deschepper Long-chain fatty acids modify hypertrophic responses of cultured primary neonatal cardiomyocytes J. Lipid Res., August 1, 2001; 42(8): 1325 - 1330. [Abstract] [Full Text] [PDF]

				A. E. Stenbit, E. B. Katz, J. C. Chatham, D. L. Geenen, S. M. Factor, R. G. Weiss, T.-S. Tsao, A. Malhotra, V. P. Chacko, C. Ocampo, et al. Preservation of glucose metabolism in hypertrophic GLUT4-null hearts Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H313 - H318. [Abstract] [Full Text] [PDF]

				B. BINAS, H. DANNEBERG, J. McWHIR, L. MULLINS, and A. J. CLARK Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization FASEB J, May 1, 1999; 13(8): 805 - 812. [Abstract] [Full Text]

				K. Kato, D. C. Chapman, H. Rupp, A. Lukas, and N. S. Dhalla Alterations of heart function and Na+-K+-ATPase activity by etomoxir in diabetic rats J Appl Physiol, March 1, 1999; 86(3): 812 - 818. [Abstract] [Full Text] [PDF]

				M. Turcani and H. Rupp Etomoxir Improves Left Ventricular Performance of Pressure-Overloaded Rat Heart Circulation, November 18, 1997; 96(10): 3681 - 3686. [Abstract] [Full Text]